1029128-58-2

Upstream product

• 1124-98-7 1-ethylcyclohexane-1-carboxylic acid 
• 4630-81-3 1-ethyl-1-methoxycarbonylcyclohexane 
• 4630-82-4 methyl cyclohexylcarboxylate 

Downstream Products

• 1029126-45-1 1-ethyl-N-(5-methyl-4-(morpholinomethyl)pyridin-2-yl)cyclohexanecarboxamide 
• 1613614-51-9 1-ethyl-N-(quinolin-8-yl)cyclohexane-1-carboxamide 
• 2891-42-1 (1-ethyl-cyclohexyl)-phenyl ketone 
• 2893-02-9 1-<1-Aethyl-cyclohexyl>-2-methyl-propan-1-on 
• 2891-49-8 1-(1-ethyl-cyclohexyl)-propan-1-one 
• 2893-06-3 1-acetyl-1-ethylcyclohexane 

Relevant academic research and scientific papers

Copper-catalyzed site-selective intramolecular amidation of unactivated C(sp3)-H bonds

The intramolecular dehydrogenative amidation of aliphatic amides, directed by a bidentate ligand, was developed using a copper-catalyzed sp3 C-H bond functionalization process. The reaction favors predominantly the C-H bonds of β-methyl groups over the unactivated methylene C-H bonds. Moreover, a preference for activating sp3 C-H bonds of β-methyl groups, via a five-membered ring intermediate, over the aromatic sp2 C-H bonds was also observed in the cyclometalation step. Additionally, sp3 C-H bonds of unactivated secondary sp3 C-H bonds could be functionalized by favoring the ring carbon atoms over the linear carbon atoms. Getting ahead on tams: The intramolecular dehydrogenative amidation of aliphatic amides, directed by a bidentate ligand, was developed using a copper-catalyzed sp 3 C-H bond functionalization process to deliver β-lactams. The reaction favors the C-H bonds of β-methyl groups over the unactivated methylene C-H bonds, as well as aromatic C(sp2)-H bonds and unactivated secondary C(sp3)-H bonds of rings.

Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists

Replacement of the phenyl ring in our previous (morpholinomethyl)aniline carboxamide cannabinoid receptor ligands with a pyridine ring led to the discovery of a novel chemical series of CB2 ligands. Compound 3, that is, 2,2-dimethyl-N-(5-methyl-4-(morpholinomethyl)pyridin-2-yl)butanamide was identified as a potent and selective CB2 agonist exhibiting in vivo efficacy after oral administration in a rat model of neuropathic pain.